Developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases


Blueprint Medicines (NASDAQ: BPMC) is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.blueprintmedicines.com

Recent News

December 12, 2017
Blueprint Medicines Announces Pricing of Public Offering of Shares of Common Stock

December 11, 2017
Blueprint Medicines Announces Proposed Public Offering of Shares of Common Stock

December 10, 2017
Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

Read More News

Associated Team Members

Alexis Borisy
Partner

Neil Exter
Partner